Mitogen-activated protein kinase (MAPK) can be phosphorylated by mitogens binding to G-protein-coupled receptors and is considered a major pathway involved in cell proliferation. In this study, we report on the activation of MAPK by muscarinic acetylcholine receptors in astroglial cells, namely the 1321N1 human astrocytoma cell line, primary rat cortical astrocytes, and fetal human astrocytes. Carbachol caused a rapid and transient phorphorylation of MAPK (ERK1/2) in all cell types, with an increase in MAPK activity, without changing the levels of MAPK proteins. Human astrocytoma cells were used to characterize the effect of carbachol on MAPK. Experiments with M 2 -and M 3 -receptor subtype-selective antagonists, and with pertussis toxin, indicated that the M 3 subtype is responsible for activating MAPK in glial cells. Pretreatment of cells with the protein kinase C (PKC) inhibitor bisindolylmaleimide I, or downregulation of PKC by 24-h treatment with the phorbol ester TPA inhibited carbachol-induced MAPK activation. Additional experiments with PKC ␣-or PKC ⑀-specific compounds indicated that the ⑀ isozyme of PKC is primarily involved in MAPK activation by carbachol. Chelation of calcium also inhibited MAPK activation by carbachol. Two MEK (MAPK kinase) inhibitors inhibited carbacholinduced DNA synthesis but only at concentrations that exceeded those sufficient to block carbachol-induced MAPK activation. Ethanol (Յ200 mM) had no effect on MAPK when present alone and did not affect carbachol-induced MAPK activation under various experimental conditions, although it inhibits carbachol-induced DNA synthesis at low concentrations (10-100 mM). These results suggest that activation of MAPK by carbachol may be necessary but not sufficient for its mitogenic effect in astroglial cells, and that does not represent a target for ethanol-induced inhibition of DNA synthesis elicited by muscarinic receptors. GLIA 35:111-120, 2001.
INTRODUCTION
Mitogen-activated protein kinase (MAPK) is a family of protein kinases that play a central role in signal transduction and thought to mediate diverse processes ranging from transcription of protooncogenes to programmed cell death (Davis, 1993; Seger and Krebs, 1995; Cobb, 1999; Garrington and Johnson, 1999; Derkinderen et al., 1999) . The best-studied MAPK are ERK1 and ERK2 (p44 and p42 MAPK), which appear to be activated by mitogens and play a central role in cell proliferation (Ferrell, 1996; Cobb, 1999) . Since the initial characterization of MAPK activation by receptor tyrosine kinases (Fantl et al., 1993) , it has subse-quently been found that many G-protein-coupled receptors also activate MAPK (Post and Brown, 1996; LopezIlasaca, 1998) .
Acetylcholine muscarinic receptors are a family of G-protein-coupled receptors comprising five subtypes (M 1 -M 5 ). Of these, three subtypes (M 1 , M 3 , and M 5 ) are coupled, through a G q , with phospholipase C, while the M 2 and M 4 subtypes inhibit adenylate cyclase via G i or G o proteins (Nathanson, 2000) . Stimulation of muscarinic receptors has been shown to activate MAPK in a variety of cellular systems. Most studies have investigated the effects of M 1 or M 3 receptors, either endogenously expressed or transfected into various cell types (Tournier et al., 1994; Quian et al., 1995; Haring et al., 1998; Larocca and Almazan, 1997; Budd et al., 1999; Rosenblum et al., 2000; Slack, 2000) . There is also evidence that M 2 muscarinic receptors can stimulate MAPK, through the G ␤␥ subunit (Crespo et al., 1994; Lopez-Ilasaca et al., 1997) . In case of M 2 receptors, the signaling to MAPK appears to involve Ras and phosphatidylinositol 3-kinase (PI3K) (Crespo et al., 1994; Lopez-Ilasaca et al., 1997) , while for the other subtypes, an involvement of protein kinase C (PKC) has been suggested, albeit with contrasting results (Kim et al., 1999; Budd et al., 1999; Keely et al., 1998; Haring et al., 1998) .
Acetylcholine has been shown to be mitogenic in a number of cellular systems, by activating muscarinic receptors (reviewed in Costa et al., 2001) . In astroglial cells, stimulation of M 3 muscarinic receptors has been found to induce DNA synthesis and cell proliferation . Yet, the ability of muscarinic agonists to activate MAPK in astroglial cells has not been investigated, with the exception of an earlier report in rat cortical astrocytes (Tournier et al., 1994) . The first aim of this study was therefore to investigate the activation of MAPK in human and rat astroglial cells by the muscarinic agonist carbachol, and the signaling pathways leading to such activation.
Ethanol has been found to be a potent inhibitor of muscarinic receptor-stimulated proliferation of astroglial cells, with an IC 50 of ϳ25 mM . Because astrocyte proliferation is a major event occurring during the brain growth spurt, a period that is exquisitely sensitive to the developmental neurotoxic affect of ethanol, such inhibition of muscarinic receptorinduced astrocyte proliferation has been suggested to be relevant in the causation of microencephaly present in the fetal alcohol syndrome (Guizzetti et al., 1997; Costa and Guizzetti, 1999) . Thus, the second aim of this study was to determine whether activation of MAPK by muscarinic receptors may represent a target for the inhibition of astroglial cell proliferation by ethanol.
MATERIALS AND METHODS Materials
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), and trypsin were purchased from GIBCO-BRL (Grand Island, NY). [Methyl- 3 H]-Thymidine (6.7 Ci/mmol) was from New England Nuclear (Boston, MA). Primary antibodies (rabbit) to the doubly-phosphorylated and the non-phosphorylated ERK1/2 proteins, and secondary antibodies (donkey, HRP-conjugated) to the rabbit IgG Fc domain were from Promega (Madison, WI), as was UO126. The kit used for measurement of MAPK activity was from New England Biolabs (Beverly, MA). The enhanced chemiluminescence (ECL) detection kit was from Amersham (Arlington, IL). Methoctramine, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), hexahydro-siladifenidol hydrochloride (HHSiD), and pertussis toxin (PTX) were from RBI (Natick, MA). Bisindolylmaleimide I, endothelin-1 (ET-1), genistein, PD98059, LY294002, and Gö6976 were from Calbiochem (La Jolla, CA). BAPTA-AM was from Molecular Probes (Eugene, OR). Ingenol-3,20-dibenzoate (IDB) was from Biomol (Plymouth Meeting, PA). All other chemicals were from Sigma Chemical Co. (St. Louis, MO).
Cell Culture
The human astrocytoma cell line 1321N1 was obtained from Dr. Joan H. Brown (UCSD, San Diego, CA). Cells were maintained in low glucose DMEM supplemented with 5% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin in 75-cm 2 flasks under a humidified atmosphere of 5% CO 2 /95% air at 37°C. For the proliferation experiments, cells were seeded onto 24-well plates; for Western blotting experiments, cells were plated onto 60-mm dishes.
Primary rat astrocytes were obtained from day 21 fetal cortices as previously described . Briefly, cortices were dissected from fetal rat brains and mechanically dissociated and incubated with trypsin, followed by trituration, repeated washing, and filtering. After counting, cells were plated at 10 7 cells/75-cm 2 tissue culture dish, precoated with poly-D-lysine, and grown in DMEM containing 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin at 37°C in 5% CO 2 /95% O 2 . After 10 days in culture, cells were shaken at high speed for 16 -18 h to remove all nonadherent cells. Cells were then harvested and plated at densities of 2-3 ϫ 10 5 in a 35-mm dish (precoated with poly-D-lysine) and grown for 3-4 days before serum deprivation and subsequent treatment. Astrocyte purity was assessed by glial fibrillary acidic protein (GFAP) staining and was Ͼ90%.
For preparation of fetal human astrocytes, tissue was provided by the Birth Defects Research Laboratory of the University of Washington; the experiments were carried out in accordance with the guidelines of the Institution. Mixed cultures were prepared from brains of legally aborted human fetuses (12-15 weeks gestation) as described by Satoh and Kim (1995) , with some modifications. In brief, brains were dissected into small blocks and incubated with trypsin followed by trituration. The resulting cell suspension was plated into poly-L-lysine-coated 75-cm 2 culture flasks at ϳ2 ϫ 10 6 cells per flask, allowed to adhere for 1 h, washed with phosphate-buffered saline (PBS), and then fed with DMEM/F12 supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were kept at 37°C in a 5% CO 2 /95% air incubator and medium was changed every 3-4 days. After 3-4 weeks, mixed cultures were trypsinized, and plated into poly-Llysine-coated 75-cm 2 culture flasks at ϳ6 ϫ 10 6 cells per flasks. This high initial seeding density allowed to enrich the cultures for astrocytes. Astrocyte purity assessed by GFAP staining was 85-90%. For the experiments, fetal human astrocytes were plated in 60-mm dishes at the density of 10 6 cells/dish. For all cell types, 48 h before mitogen treatment, the plates were washed twice with PBS, and serum-free medium was added (DMEM with 0.1% bovine serum albumin [BSA] ).
Ethanol and Drug Treatments
Pertussis toxin (10 -100 ng/ml) was added to cells 20 h before treatment with mitogens. To downregulate PKC, 12-O-tetradecanoyl phorbol-13-acetate (TPA) (500 nM) was added to cells 24 h before agonist treatment. All other inhibitors were added 30 min before agonists. For ethanol treatments longer than 4 h, cell culture plates were placed in dishes containing the same concentration of ethanol, to minimize evaporation.
Measurement of DNA Synthesis

Incorporation of [
3 H]thymidine into replicating DNA was measured as described previously . Briefly, 24 h after mitogen addition, with 1 Ci/ well [ 3 H]thymidine included for the last 6 h of incubation, cells were washed twice with PBS. The adherent cells were fixed in methanol and the DNA was precipitated with 10% trichloroacetic acid (TCA), dissolved in 500 l 1 N NaOH, and DNA-incorporated radioactivity was quantitated in a Beckmann LS 5000 CE scintillation counter.
Measurements of MAPK Activation
After treatment, cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (w/v) Nonidet P-40 (NP-40), 0.1% sodium dodecyl sulfate (SDS), 0.1% Triton-X 100, 5 mM Na pyrophosphate, 10 mM Na ␤-glycerophosphate, 1 mM Na orthovanadate, and protease inhibitor cocktail); the cell extract was cleared by centrifugation for 15 min at 12,000g at 4°C. Protein concentration was measured by the Bradford method; 20 -60 g of proteins was loaded onto a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. After electophoresis and protein transfer, membranes were probed with the anti-phospho-MAPK antibody. After probing with a horseradish peroxidase (HRP)-conjugated secondary antibody, membranes were treated with enhanced chemiluminescence (ECL) reagents (Amersham) and exposed to Kodak X-Omat film. Densitometry of exposed films was performed on a Bio-Rad GelDoc 1000, and quantitated with Molecular Analyst software, version 2.1.1 (Bio-Rad), on a Macintosh computer. For measurements of MAPK levels, a polyclonal antibody against nonphosphorylated ERK1 and ERK2 was used.
To measure MAPK activity, a kit from New England Biolabs was used following the directions of the manufacturer. Briefly, cells were harvested in a lysis buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerol phosphate, 1 mM sodium orthovanadale, 1 g/ml leupeptin, and 15% final volume protease inhibitor cocktail, and MAPK was immunoprecipitated. The immune complexes were washed twice with lysis buffer, and then twice with kinase buffer containing 25 mM Tris, pH 7.5, 5 mM glycerol phosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 , 10 mM MgCl 2 . Each complex was suspended in 25 l of kinase buffer to which 200 M ATP, and 1 g Elk-1 fusion protein was added for a 30 min incubation at 30°C. The reaction was terminated with 15 l 3ϫ SDS sample buffer. The samples were analyzed by SDS-PAGE and Western blot (as described above) using phospho-specific Elk-1 antibody as primary antibody and a horseradish peroxidase-conjugated donkey anti-rabbit antibody as secondary antibody. Antibody-bound proteins were detected using an enhanced chemiluminescence ECL Western blotting analysis system, and the membranes were exposed to Kodak X-Omat film.
Data Analysis
Each experiment was repeated at least three times. Statistical analysis was performed with the Statview 512 program on a Macintosh computer; one-way analysis of variance (ANOVA), followed by Fisher's least significant difference test (one-tailed) was used to determine significant differences (P Ͻ 0.05) from untreated controls.
RESULTS
The cholinergic agonist carbachol caused activation of MAPK in astroglial cells. A time-course experiment in human 1321N1 astrocytoma cells (Fig. 1A) showed that carbachol caused a rapid activation of ERK1 and 2 with a maximum at 5-15 min, and a decrease over 60 min, by which time it had returned to basal level. Concentration-response experiments with carbachol showed that maximal activation was achieved at 0.1 mM in the astrocytoma cell line (Fig. 1B) . The increase of MAPK phosphorylation was accompanied by an increase in MAPK activity, measured by phosphorylation of the MAPK substrate Elk 1, without any change in the levels of MAPK protein (Fig. 1A) . In primary cultures of fetal human astrocytes carbachol caused a similar increase in phosphorylated ERK1 and 2, and an increase in MAPK activity ( Fig. 2A) . The dose-dependent activation of MAPK in rat cortical astrocytes is shown in Figure 2B .
Carbachol-induced activation of MAPK was due to activation of muscarinic receptors, as shown by its inhibition by atropine (Fig. 3A) . Human 1321N1 astrocytoma cells and rat cortical astrocytes express mainly the M 2 and M 3 subtypes of muscarinic receptors (with a negligible amount of M 5 ) . Figure 3A shows that in astrocytoma cells the M 2 -selective antagonists methoctramine and gallamine had no effect on MAPK, while the M 3 -selective antagonists 4-DAMP and HHSiD caused nearly total inhibition of carbachol-induced MAPK activation. Similar results were obtained in rat cortical astrocytes (Fig.   3B ). To substantiate these findings, the ability of pertussis toxin (PTX) to inhibit carbachol-stimulated MAPK in 1321N1 cells was investigated. PTX ADPribosylates newly synthesized G i proteins, blocking their ability to interact with the M 2 muscarinic receptor. PTX strongly inhibited MAPK activation by endothelin (ET-1), whose receptor is linked to a PTX-sensitive G protein (Kasuya et al., 1994) , but had no effect on MAPK activation by carbachol (Fig. 3C) . Similar effects were also seen in rat cortical astrocytes (Fig. 3D) . PTX (1-200 ng/ml) also had no effect on carbachol-induced DNA synthesis in astrocytoma cells (not shown), confirming previous studies which indicated that proliferation is primarily mediated by activation of M 3 muscarinic receptors . Two different inhibitors of MEK, the kinase that directly phosphorylates MAPK, PO98059, and UO126, blocked the abil- Fig. 1 . Mitogen-activated protein kinase (MAPK) activation by carbachol in 1321N1 human astrocytoma cells. A: Time course. Cells were treated with 1 mM carbachol for the times indicated. Levels of phosphorylated ERK1/2, MAPK activity, and protein levels of ERK1/2 were determined as described under Materials and Methods. B: Dose response. Cells were treated with carbachol at the concentrations indicated for 5 min; Phospho ERK1/2 were detected by Western blotting. Bars represent the mean (ϮSEM) of three independent experiments. All carbachol groups are significantly different from control (P Ͻ 0.05). Representative blot from one experiment is shown below. Fig. 2 . Mitogen-activated protein kinase (MAPK) activation by carbachol in fetal human astrocytes and rat cortical astrocytes. Human and rat astrocytes were prepared as described in Methods. A: Carbachol-induced increases MAPK phosphorylation and activity in fetal human astrocytes. Blots show the result of a single experiment that was repeated three times with similar results. B: Carbachol-induced increase in MAPK phosphorylation in rat cortical astrocytes. Cells were treated with carbachol for 15 min; phospho ERK1/2 were detected by Western blotting. Bars represent the mean (ϮSEM) of three independent experiments. All carbachol groups are significantly different from control (P Ͻ 0.05).
ity of carbachol to activate MAPK in 1321N1 cells (Fig.  4A) . Carbachol-induced DNA synthesis was also decreased by both MEK inhibitors (Fig. 4B) . However, at concentrations that completely blocked MAPK activation, a significant proliferative response by carbachol was still present.
To investigate the role of PKC in the activation of MAPK by carbachol in glial cells, the PKC inhibitor bisindolylmaleimide I and downregulation of PKC by a 24-h pretreatment with TPA were used. Figure 5A shows that both treatments caused significant inhibition of carbachol activation of MAPK in 1321N1 cells; Fig. 3 . Effects of muscarinic antagonists and of pertussis toxin on carbachol-mediated mitogen-activated protein kinase (MAPK) activation in human astrocytoma cells and rat astrocytes. A: Astrocytoma cells were pretreated with antagonists (1 M) for 30 min, then 1 mM carbachol was added for 5 min, and activation of ERK1/2 was determined by Western blotting. Mecamylamine (Mec) and atropine (Atr) were used to distinguish nicotinic and muscarinic responses, respectively; the M 2 -selective antagonists used were methoctramine (Met) and gallamine (Gal), and the M 3 -selective antagonists used were 4-DAMP (Damp) and HHSiD (Hsi). Bars represent the mean (ϮSEM) of three independent experiments; *P Ͻ 0.05. B: Rat cortical astrocytes were pretreated with M 2 or M 3 selective antagonists and activation of ERK1/2 was determined by Western blot, 15 min after addition of carbachol. Compounds and concentrations were the same as in A. The blot is representative of a single experiment that was repeated three times with similar results. C: Astrocytoma cells were treated for 18 h with the indicated concentrations of pertussis toxin (ng/ml), followed by treatment with 1 mM carbachol or 100 nM endothelin-1 (ET-1) for 5 min. Bars represent the mean (ϮSEM) of three independent experiments; *P Ͻ 0.05. D: Rat cortical astrocytes were treated for 18 h with pertussis toxin (100 ng/ml), followed by treatment with 1 mM carbachol or 100 nM endothelin-1 for 15 min. Bars represent the mean (ϮSEM) of three independent experiments; *P Ͻ 0.05.
identical results were obtained in rat cortical astrocytes, and when cells were stimulated with TPA (data not shown). Since 1321N1 human astrocytoma cells have been shown to express only the ␣, ⑀, and -isozymes of PKC (Post et al., 1996) , we next tested the involvement of the two TPA-sensitive isozymes (␣ and ⑀) in carbachol activation of MAPK. To determine the involvement of PKC ␣, we used two different approaches. In the first treatment, 1321N1 cells were incubated for 24 h with lead acetate (100 M) before carbachol stimulation; this treatment causes a selective downregulation of PKC ␣ without affecting PKC ⑀ and without causing cytotoxicity (Lu et al., 1999) . The second approach was to pretreat 1321N1 cells with Gö6976, a selective PKC ␣ inhibitor, before carbachol stimulation (Martiny-Baron et al., 1993) . Neither treatment affected the ability of carbachol to activate MAPK (Fig. 5B) , indicating a lack of involvement of PKC ␣ in this effect. In an additional experiment, astrocytoma cells were incubated with ingenol 3,20-dibenzoate (IDB), a specific activator of PKC ⑀, which has been shown to downregulate this PKC isozyme selectively after prolonged incubation (Kim et al., 1999) . A 24-h preincubation with IDB caused a significant dose-dependent reduction in carbachol-mediated MAPK activation (Fig. 5B) , suggesting that PKC ⑀ is involved in MAPK activation by muscarinic agonists. To examine the role of Ca 2ϩ in MAPK activation by carbachol, astrocytoma cells were pretreated with BAPTA-AM, a chelator of intracellular Ca 2ϩ ; this treatment blocked the ability of carbachol to activate MAPK in human astrocytoma cells (Fig. 6) , as well as in rat astrocytes (data not shown).
Several studies have reported that MAPK activation by G ␤␥ is mediated by phosphatidyl inositol-3-kinase (PI3K), and that tyrosine kinases may also play a role in the G ␤␥ pathway (Crespo et al., 1994; Lopez-Ilasaca et al., 1997; Lopez-Ilasaca, 1998) . Specific inhibitors of PI3K and tyrosine kinases were thus tested for their ability to inhibit carbachol activation of MAPK in astrocytoma cells (Fig. 7) . The PI3K-specific inhibitor LY294002 and genistein, a fairly broad-spectrum tyrosine kinase inhibitor, decreased carbachol-induced MAPK activation, but only at concentrations that exceeded those required specifically to inhibit their respective targets (Choudhury et al., 1997; Akiyama et al., 1987) . This suggests that a G ␤␥ -mediated activation of MAPK via PI3K or tyrosine kinase is not a relevant pathway in this cell type.
As ethanol has been shown to inhibit carbachol-mediated glial proliferation at relevant physiological concentrations , we tested the hypothesis that MAPK, a central component of the activation pathway leading to cell proliferation, would be a target of ethanol's inhibitory effects (Fig. 8A ). However, ethanol (100 and 200 mM) had no visible effect on carbachol activation of MAPK, with either short (30 min) or long (24 h; not shown) pretreatment times. Similar results were observed in rat cortical astrocytes (Fig. 8B) . In none of the conditions tested did ethanol have any effect on MAPK when present alone.
DISCUSSION
The main finding of this study is that stimulation of muscarinic receptors in three different astroglial cell models in vitro leads to activation of MAPK. Carbachol stimulation of human astrocytoma cells, rat cortical astrocytes and fetal human astrocytes resulted in a rapid and transient phosphorylation of ERK1/2 and in an increase of MAPK activity without a parallel change in the levels of MAPK protein. This signaling pathway is involved in muscarinic receptor-induced proliferation of astroglial cells, but it does not appear to be the only determinant, and does not mediate the ability of ethanol to inhibit carbachol-induced DNA synthesis in these cells.
A number of studies in other cell systems have indicated that stimulation of M 1 or M 3 muscarinic receptors can lead to activation of MAPK. These include Cos-1 and Cos-7 cells, Chinese hamster ovary (CHO) cells, PC12 cells, 3T3 cells or human embryonic kidney cells transfected with either receptor subtype (Qian et al., 1995; Haring et al., 1998; Budd et al., 1999; Nicke et al., 1999; Slack, 2000; Rosenblum et al., 2000) , T84 colonic epithelial cells (Keely et al., 1998) , PC12 cells (Berkeley and Levey, 2000) , human neuroblastoma SK-N-BE2 (C) cells (Kim et al., 1999) , primary cortical neurons (Rosenblum et al., 2000) , and oligodendrocyte progenitors (Larocca and Almazan, 1997) . In astroglial cells, the only evidence so far was provided by findings in rat cortical astrocytes (Tournier et al., 1994) . There is evidence that muscarinic receptors of the M 2 and M 4 subtype can activate MAPK through the G ␤␥ subunit, as shown by experiments in transfected cells (Winitz et al., 1993; Crespo et al., 1994; Lopez-Ilasaca et al., 1997) . Human 1321N1 astrocytoma cells and rat cortical astrocytes express M 2 , M 3 and to a minor degree M 5 , muscarinic receptor mRNA , while fetal human astrocytes appear to express all five muscarinic receptor subtypes (Elhusseiny et al., 1999) . Experiments carried out in 1321N1 astrocytoma cells and rat astrocytes with M 2 and M 3 muscarinic receptor antagonists and with PTX suggested that MAPK activation by carbachol is primarily mediated by the M 3 muscarinic receptor subtype.
Contrasting results have been obtained on whether muscarinic M 1 or M 3 receptor-induced activation of MAPK is PKC-dependent or independent. A lack of effect by PKC down regulation or PKC inhibitors has been reported by some investigators (Larocca and Almazan, 1997; Keely et al., 1998; Haring et al., 1998; Rosenblum et al., 2000) . By contrast, others have reported that under these conditions, the effect of muscarinic agonists on MAPK is partially (Slack, 2000) or completely (Tournier et al., 1994; Budd et al., 1999; Kim et al., 1999; Berkeley and Levey, 2000) blocked. Our results in human astrocytoma cells are in agreement with the latter findings and further indicated a selective involvement of PKC ⑀, similar to what was reported earlier by Kim et al. (1999) . Though the PKC ⑀ isozyme is calcium-independent, surprisingly we found that carbachol-induced MAPK activation in astroglial cells was inhibited by the calcium chelator BAPTA-AM. This finding is in agreement with that by Larocca and Almazan (1997) in oligodendrocyte precursors, where, however, activation of MAPK by carbachol was not dependent on TPA-sensitive PKC. G-protein-coupled receptors may also activate MAPK through G ␤␥ subunits. In most instances, it appears that G ␤␥ activates MAPK through a pathway that includes considerable overlap with that of typical receptor tyrosine kinase activation (Crespo et al., 1994; Hawes et al., 1995) . Specifically, in many cell types, the G ␤␥ subunit activates MAPK in a pathway that is PI3K-, Ras-, and often tyrosine-kinase-dependent as well (Lopez-Ilasaca et al., 1997; Coso et al., 1996; Igishi et al., 1998) . The M 2 muscarinic receptor for example, has been shown to mediate its activation of MAPK via G ␤␥ using a PI3K-and tyrosine-kinase-dependent signal pathway (Winitz, et al., 1993; Lopez-Ilasaca, et al., 1997; Igishi et al., 1998) . In the present study, however, the results using inhibitors specific to PI3K (LY294002) and tyrosine-kinases (genistein), suggest that these signaling intermediates do not play a substantial role in muscarinic M 3 receptor-mediated activation of MAPK in astroglial cells. Indeed, while both compounds inhibited carbachol-induced activation of MAPK, they did so at concentrations that greatly exceeded those capable of inhibiting PI-3K (LY294002 IC 50 ϭ 1.4 M) or tyrosine kinase (genistein IC 50 ϭ 2.6 M) (Vlahos et al., 1994) . Other investigators have reported both an inhibitory (Rosenblum et al., 2000) and a lack of effect (Kim et al., 1999) of PI3K inhibitors on induction of MAPK by carbachol. Haring et al. (1998) also reported that genistein was unable to block muscarinic receptor-induced MAPK activation in PC12M1 cells.
Activation of muscarinic receptors leads to increased DNA synthesis in human 1321N1 astrocytoma cells, rat cortical astrocytes and fetal human astrocytes (Guizzetti, Möller and Costa, unpublished results) . A role for MAPK activation in increased astroglial cell proliferation is supported by the finding that two MEK inhibitors, UO126 and PD98059, were effective inhibitors of carbachol-induced DNA synthesis. However, at concentrations capable of totally blocking carbachol-induced MAPK activation, both MEK inhibitors caused only partial inhibition of carbachol-induced DNA synthesis. It would then appear that activation of MAPK by carbachol may be necessary but not sufficient for its full mitogenic effect in astroglial cells. Support for this hypothesis is provided by the findings that carbacholinduced MAPK activation is found in cells expressing only M 2 muscarinic receptors, which are not associated with a mitogenic response (Winitz et al., 1993) , in cells that do not respond to carbachol with an increased DNA synthesis (Berkeley and Levey, 2000) , and under conditions in which cell growth is either inhibited or stimulated (Nicke et al., 1999) .
Further evidence of this limited role of MAPK activation in carbachol-induced DNA synthesis in astroglial cells was provided by experiments with ethanol. Ethanol has been shown to inhibit muscarinic receptorinduced astroglial cell proliferation in a range of concentrations of 10 -100 mM . However, at concentrations of 100, or even 200 mM, ethanol had no effect on carbachol-induced MAPK activation, even with prolonged incubation times, suggesting that this pathway may not be a relevant target for the inhibitory effect of ethanol on DNA synthesis.
These results are similar to those reported in another glial cell type, C6 glioma cells, in which MAPK activation was found to be unaffected by ethanol pretreatment (Sato et al., 1999) . A similar lack of effect of ethanol was also recently reported in a study in fibroblasts . Ethanol has been shown to inhibit MAPK activation by various stimuli, however, in hepatocellular carcinoma cells (Banerjee et al., 1998) , vascular smooth muscle cells (Hendrickson et al., 1998) , osteoblasts (Klein et al., 1996) , and in vivo in hepatocytes (Chen et al., 1998) , rat hippocampus (Davis et al., 1999) , and alveolar macrophages (Ouyang et al., 1998) . In rat astrocytes, ethanol has been reported to inhibit the PKC-independent acute activation of MAPK by PDGF, but to potentiate the PKC-dependent, sustained activation of MAPK (Luo and Miller 1999a) . We could not detect any stimulation of MAPK by ethanol alone, even at high concentrations, and after different times of incubation. However, positive effects of ethanol treatment alone on MAPK activation have been found in hepatocytes (McKillop et al., 1999) , neuroblastoma cells (Luo and Miller, 1999b) , fibroblasts , as well as rat cortical astrocytes (Luo and Miller 1999a) . The cell-specific and receptor-specific effects of ethanol reported in the literature thus preclude any generalization about ethanol exposure and MAPK. The lack of an ethanol effect on MAPK activation in astroglial cells does suggest, however, that there is a second, non-MAPK, pathway that is responsible for carbachol-mediated proliferation in this cell type, as cholinergic proliferation has been shown to be quite sensitive to ethanol inhibition . It has indeed been recently reported that other pathways, e.g., activation of the atypical PKC and of p70S6 kinase by carbachol, are sensitive targets for ethanol within the 10-100 -mM range (Guizzetti and Costa, 2000a,b) .
